2,5,6,7-Tetramethyl-s-triazolo<1,5-a>pyrimidin | 90942-52-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并嘧啶类
• 英文名称: 2,5,6,7-Tetramethyl-s-triazolo<1,5-a>pyrimidin
• 英文别名: 2,5,6,7-tetramethyl-[1,2,4]triazolo[1,5-a]pyrimidine；tetramethyl-[1,2,4]triazolo[1,5-a]pyrimidine；Tetramethyl-[1,2,4]triazolo[1,5-a]pyrimidin；2,5,6,7-Tetramethyl-[1,2,4]triazolo[1,5-a]pyrimidine
• CAS: 90942-52-2
• 化学式: C₉H₁₂N₄
• 分子量: 176.221
• InChiKey: PCGBIBQVPSLKPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2,4-己二酮 、 3-氨基-5-甲基-4H-1,2,4-三唑 在 乙醇 作用下， 生成 2,5,6,7-Tetramethyl-s-triazolo<1,5-a>pyrimidin
  参考文献：
  名称：

  Buelow; Haas, Chemische Berichte, 1910, vol. 43, p. 377

  摘要：

  DOI：

文献信息

• Triazolopyrimidine compounds and their use in treating cancer
  申请人：Dizal (Jiangsu) Pharmaceutical Co., Ltd.

  公开号：US11084827B2

  公开（公告）日：2021-08-10

  The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Ring A, Ring B and Ring C have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating MCT4 mediated diseases.

  本发明涉及式（I）化合物： 或其药学上可接受的盐，其中 R1、R2、X、环 A、环 B 和环 C 具有本文在描述中定义的任何含义；它们的制备工艺；含有它们的药物组合物以及它们在治疗 MCT4 介导的疾病中的用途。
• TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER
  申请人：DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.

  公开号：EP3790879B1

  公开（公告）日：2022-06-29
• CCR9 ANTAGONIST COMPOUNDS
  申请人：Pandya Bhuamik

  公开号：US20170216295A1

  公开（公告）日：2017-08-03

  Provided herein are compounds that inhibit CCR9 receptor function. Also provided herein are methods of treating inflammatory disease in a subject, comprising administering to the subject a compound of the invention. Accordingly, in one aspect, provided herein is a compound of Formula (1) or a pharmaceutically acceptable salt thereof. In another aspect, provided herein is a pharmaceutical composition, comprising a compound of Formula (1), and a pharmaceutically acceptable carrier.
• US7329663B2
  申请人：——

  公开号：US7329663B2

  公开（公告）日：2008-02-12
• [EN] TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER<br/>[FR] COMPOSÉS DE TRIAZOLOPYRIMIDINE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2019215316A1

  公开（公告）日：2019-11-14

  The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2 , X, Ring A, Ring B and Ring C have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating MCT4 mediated diseases.